Document Detail

Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study.
MedLine Citation:
PMID:  16382002     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: There has been a growing interest in treating postmenopausal women with androgens. However, hyperandrogenemia in females has been associated with increased risk of cardiovascular disease. OBJECTIVE: We aimed to assess the effects of androgen replacement on cardiovascular risk factors. DESIGN: Thirty-seven postmenopausal women aged 42-62 years that had undergone hysterectomy were prospectively enrolled in a double-blind protocol to receive, for 12 months, percutaneous estradiol (E2) (1 mg/day) combined with either methyltestosterone (MT) (1.25 mg/day) or placebo. METHODS: Along with treatment, we evaluated serum E2, testosterone, sex hormone-binding globulin (SHBG), free androgen index, lipids, fibrinogen, and C-reactive protein; glucose tolerance; insulin resistance; blood pressure; body-mass index; and visceral and subcutaneous abdominal fat mass as assessed by computed tomography. RESULTS: A significant reduction in SHBG (P < 0.001) and increase in free testosterone index (P < 0.05; Repeated measures analysis of variance) were seen in the MT group. Total cholesterol, triglycerides, fibrinogen, and systolic and diastolic blood pressure were significantly lowered to a similar extent by both regimens, but high-density lipoprotein cholesterol decreased only in the androgen group. MT-treated women showed a modest rise in body weight and gained visceral fat mass relative to the other group (P < 0.05), but there were no significant detrimental effects on fasting insulin levels and insulin resistance. CONCLUSION: This study suggests that the combination of low-dose oral MT and percutaneous E2, for 1 year, does not result in expressive increase of cardiovascular risk factors. This regimen can be recommended for symptomatic postmenopausal women, although it seems prudent to perform baseline and follow-up lipid profile and assessment of body composition, especially in those at high risk of cardiovascular disease.
Lenora M Camarate S M Leão; Mônica Peres C Duarte; Dalva Margareth B Silva; Paulo Roberto V Bahia; Cláudia Medina Coeli; Maria Lucia Fleiuss de Farias
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  154     ISSN:  0804-4643     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-29     Completed Date:  2006-03-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  131-9     Citation Subset:  IM    
Service of Endocrinology, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abdominal Fat / anatomy & histology,  drug effects*
Acute-Phase Proteins / metabolism*
Administration, Oral
Blood Glucose / metabolism*
Blood Pressure / drug effects
C-Reactive Protein / metabolism
Estrogen Replacement Therapy*
Fibrinogen / metabolism
Lipids / blood*
Methyltestosterone / administration & dosage,  therapeutic use*
Middle Aged
Sex Hormone-Binding Globulin / metabolism
Reg. No./Substance:
0/Acute-Phase Proteins; 0/Blood Glucose; 0/Lipids; 0/Sex Hormone-Binding Globulin; 58-18-4/Methyltestosterone; 9001-32-5/Fibrinogen; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Postnatal penile length and growth rate correlate to serum testosterone levels: a longitudinal study...
Next Document:  Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in t...